Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy

Pavel Klein, Daniel Herr, Phillip L. Pearl, JoAnne E Natale, Zachary Levine, Claude Nogay, Fabian Sandoval, Stacey Trzcinsky, Shireen M. Atabaki, Tammy Tsuchida, John van den Anker, Steven J. Soldin, Jianping He, Robert McCarter

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Levetiracetam (LEV) has antiepileptogenic effects in animals and is a candidate for prevention of epilepsy after traumatic brain injury. Pharmacokinetics of LEV in TBI patients was unknown. We report pharmacokinetics of TBI subjects≥6years with high PTE risk treated with LEV 55mg/kg/day orally, nasogastrically or intravenously for 30days starting ≤8h after injury in a phase II safety and pharmacokinetic study. Forty-one subjects (26 adults and 15 children) were randomized to PK studies on treatment days 3 and 30. Thirty-six out of forty-one randomized subjects underwent PK study on treatment day 3, and 24/41 subjects underwent PK study on day 30. On day 3, mean Tmax was 2.2h, Cmax was 60.2μg/ml and AUC was 403.7μg/h/ml. Tmax was longer in the elderly than in children and non-elderly adults (5.96h vs. 1.5h and 1.8h; p=0.0001). AUC was non-significantly lower in children compared with adults and the elderly (317.4μg/h/ml vs. 461.4μg/h/ml and 450.2μg/h/ml; p=0.08). Cmax trended higher in i.v.- versus tablet- or n.g.-treated subjects (78.4μg/ml vs. 59μg/ml and 48.2μg/ml; p=0.07). AUC of n.g. and i.v. administrations was 79% and 88% of AUC of oral administration. There were no significant PK differences between days 3 and 30. Treatment of TBI patients with high PTE risk with 55mg/kg/day LEV, a dose with antiepileptogenic effect in animals, results in plasma LEV levels comparable to those in animal studies.

Original languageEnglish (US)
Pages (from-to)457-461
Number of pages5
JournalEpilepsy and Behavior
Volume24
Issue number4
DOIs
StatePublished - Aug 2012
Externally publishedYes

Fingerprint

etiracetam
Post-Traumatic Epilepsy
Pharmacokinetics
Area Under Curve
Tablets
Oral Administration
Epilepsy
Therapeutics
Safety

Keywords

  • Epilepsy
  • Epilepsy prevention
  • Head injury
  • Levetiracetam
  • Pharmacokinetics
  • Post-traumatic epilepsy
  • Saliva
  • Seizures
  • Traumatic brain injury

ASJC Scopus subject areas

  • Clinical Neurology
  • Behavioral Neuroscience
  • Neurology

Cite this

Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy. / Klein, Pavel; Herr, Daniel; Pearl, Phillip L.; Natale, JoAnne E; Levine, Zachary; Nogay, Claude; Sandoval, Fabian; Trzcinsky, Stacey; Atabaki, Shireen M.; Tsuchida, Tammy; van den Anker, John; Soldin, Steven J.; He, Jianping; McCarter, Robert.

In: Epilepsy and Behavior, Vol. 24, No. 4, 08.2012, p. 457-461.

Research output: Contribution to journalArticle

Klein, P, Herr, D, Pearl, PL, Natale, JE, Levine, Z, Nogay, C, Sandoval, F, Trzcinsky, S, Atabaki, SM, Tsuchida, T, van den Anker, J, Soldin, SJ, He, J & McCarter, R 2012, 'Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy', Epilepsy and Behavior, vol. 24, no. 4, pp. 457-461. https://doi.org/10.1016/j.yebeh.2012.05.011
Klein, Pavel ; Herr, Daniel ; Pearl, Phillip L. ; Natale, JoAnne E ; Levine, Zachary ; Nogay, Claude ; Sandoval, Fabian ; Trzcinsky, Stacey ; Atabaki, Shireen M. ; Tsuchida, Tammy ; van den Anker, John ; Soldin, Steven J. ; He, Jianping ; McCarter, Robert. / Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy. In: Epilepsy and Behavior. 2012 ; Vol. 24, No. 4. pp. 457-461.
@article{c3746cb128384ac3bc59296866b30e1d,
title = "Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy",
abstract = "Levetiracetam (LEV) has antiepileptogenic effects in animals and is a candidate for prevention of epilepsy after traumatic brain injury. Pharmacokinetics of LEV in TBI patients was unknown. We report pharmacokinetics of TBI subjects≥6years with high PTE risk treated with LEV 55mg/kg/day orally, nasogastrically or intravenously for 30days starting ≤8h after injury in a phase II safety and pharmacokinetic study. Forty-one subjects (26 adults and 15 children) were randomized to PK studies on treatment days 3 and 30. Thirty-six out of forty-one randomized subjects underwent PK study on treatment day 3, and 24/41 subjects underwent PK study on day 30. On day 3, mean Tmax was 2.2h, Cmax was 60.2μg/ml and AUC was 403.7μg/h/ml. Tmax was longer in the elderly than in children and non-elderly adults (5.96h vs. 1.5h and 1.8h; p=0.0001). AUC was non-significantly lower in children compared with adults and the elderly (317.4μg/h/ml vs. 461.4μg/h/ml and 450.2μg/h/ml; p=0.08). Cmax trended higher in i.v.- versus tablet- or n.g.-treated subjects (78.4μg/ml vs. 59μg/ml and 48.2μg/ml; p=0.07). AUC of n.g. and i.v. administrations was 79{\%} and 88{\%} of AUC of oral administration. There were no significant PK differences between days 3 and 30. Treatment of TBI patients with high PTE risk with 55mg/kg/day LEV, a dose with antiepileptogenic effect in animals, results in plasma LEV levels comparable to those in animal studies.",
keywords = "Epilepsy, Epilepsy prevention, Head injury, Levetiracetam, Pharmacokinetics, Post-traumatic epilepsy, Saliva, Seizures, Traumatic brain injury",
author = "Pavel Klein and Daniel Herr and Pearl, {Phillip L.} and Natale, {JoAnne E} and Zachary Levine and Claude Nogay and Fabian Sandoval and Stacey Trzcinsky and Atabaki, {Shireen M.} and Tammy Tsuchida and {van den Anker}, John and Soldin, {Steven J.} and Jianping He and Robert McCarter",
year = "2012",
month = "8",
doi = "10.1016/j.yebeh.2012.05.011",
language = "English (US)",
volume = "24",
pages = "457--461",
journal = "Epilepsy and Behavior",
issn = "1525-5050",
publisher = "Academic Press Inc.",
number = "4",

}

TY - JOUR

T1 - Results of phase II pharmacokinetic study of levetiracetam for prevention of post-traumatic epilepsy

AU - Klein, Pavel

AU - Herr, Daniel

AU - Pearl, Phillip L.

AU - Natale, JoAnne E

AU - Levine, Zachary

AU - Nogay, Claude

AU - Sandoval, Fabian

AU - Trzcinsky, Stacey

AU - Atabaki, Shireen M.

AU - Tsuchida, Tammy

AU - van den Anker, John

AU - Soldin, Steven J.

AU - He, Jianping

AU - McCarter, Robert

PY - 2012/8

Y1 - 2012/8

N2 - Levetiracetam (LEV) has antiepileptogenic effects in animals and is a candidate for prevention of epilepsy after traumatic brain injury. Pharmacokinetics of LEV in TBI patients was unknown. We report pharmacokinetics of TBI subjects≥6years with high PTE risk treated with LEV 55mg/kg/day orally, nasogastrically or intravenously for 30days starting ≤8h after injury in a phase II safety and pharmacokinetic study. Forty-one subjects (26 adults and 15 children) were randomized to PK studies on treatment days 3 and 30. Thirty-six out of forty-one randomized subjects underwent PK study on treatment day 3, and 24/41 subjects underwent PK study on day 30. On day 3, mean Tmax was 2.2h, Cmax was 60.2μg/ml and AUC was 403.7μg/h/ml. Tmax was longer in the elderly than in children and non-elderly adults (5.96h vs. 1.5h and 1.8h; p=0.0001). AUC was non-significantly lower in children compared with adults and the elderly (317.4μg/h/ml vs. 461.4μg/h/ml and 450.2μg/h/ml; p=0.08). Cmax trended higher in i.v.- versus tablet- or n.g.-treated subjects (78.4μg/ml vs. 59μg/ml and 48.2μg/ml; p=0.07). AUC of n.g. and i.v. administrations was 79% and 88% of AUC of oral administration. There were no significant PK differences between days 3 and 30. Treatment of TBI patients with high PTE risk with 55mg/kg/day LEV, a dose with antiepileptogenic effect in animals, results in plasma LEV levels comparable to those in animal studies.

AB - Levetiracetam (LEV) has antiepileptogenic effects in animals and is a candidate for prevention of epilepsy after traumatic brain injury. Pharmacokinetics of LEV in TBI patients was unknown. We report pharmacokinetics of TBI subjects≥6years with high PTE risk treated with LEV 55mg/kg/day orally, nasogastrically or intravenously for 30days starting ≤8h after injury in a phase II safety and pharmacokinetic study. Forty-one subjects (26 adults and 15 children) were randomized to PK studies on treatment days 3 and 30. Thirty-six out of forty-one randomized subjects underwent PK study on treatment day 3, and 24/41 subjects underwent PK study on day 30. On day 3, mean Tmax was 2.2h, Cmax was 60.2μg/ml and AUC was 403.7μg/h/ml. Tmax was longer in the elderly than in children and non-elderly adults (5.96h vs. 1.5h and 1.8h; p=0.0001). AUC was non-significantly lower in children compared with adults and the elderly (317.4μg/h/ml vs. 461.4μg/h/ml and 450.2μg/h/ml; p=0.08). Cmax trended higher in i.v.- versus tablet- or n.g.-treated subjects (78.4μg/ml vs. 59μg/ml and 48.2μg/ml; p=0.07). AUC of n.g. and i.v. administrations was 79% and 88% of AUC of oral administration. There were no significant PK differences between days 3 and 30. Treatment of TBI patients with high PTE risk with 55mg/kg/day LEV, a dose with antiepileptogenic effect in animals, results in plasma LEV levels comparable to those in animal studies.

KW - Epilepsy

KW - Epilepsy prevention

KW - Head injury

KW - Levetiracetam

KW - Pharmacokinetics

KW - Post-traumatic epilepsy

KW - Saliva

KW - Seizures

KW - Traumatic brain injury

UR - http://www.scopus.com/inward/record.url?scp=84864302215&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864302215&partnerID=8YFLogxK

U2 - 10.1016/j.yebeh.2012.05.011

DO - 10.1016/j.yebeh.2012.05.011

M3 - Article

VL - 24

SP - 457

EP - 461

JO - Epilepsy and Behavior

JF - Epilepsy and Behavior

SN - 1525-5050

IS - 4

ER -